Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the [….]
Representatives from Johnson & Johnson Innovation will provide an overview of goals and mission, highlighting how Johnson & Johnson Innovation interacts with the entrepreneurial community through JLABS, JJDC, The Innovation Centers and Janssen Business & Development.
Q&A With BeneVir Co-Founder and COO, Katherine Sacksteder, PhD – The Path to a Landmark Acquisition (Part 1) October 9, 2018 This has been a year marked by many notable biotech deals, especially in the immunotherapy market. One deal, in particular, has generated more local excitement in the BioHealth Capital Region than any other; that is [….]
